These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31699606)

  • 1. Novel benzimidazole phosphonates as potential inhibitors of protein prenylation.
    Bhuiyan NH; Varney ML; Wiemer DF; Holstein SA
    Bioorg Med Chem Lett; 2019 Dec; 29(24):126757. PubMed ID: 31699606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
    Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
    Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.
    Wiemer AJ; Yu JS; Shull LW; Barney RJ; Wasko BM; Lamb KM; Hohl RJ; Wiemer DF
    Bioorg Med Chem; 2008 Apr; 16(7):3652-60. PubMed ID: 18308574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids.
    Hohl RJ; Lewis KA; Cermak DM; Wiemer DF
    Lipids; 1998 Jan; 33(1):39-46. PubMed ID: 9470172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
    Wasko BM; Dudakovic A; Hohl RJ
    J Pharmacol Exp Ther; 2011 May; 337(2):540-6. PubMed ID: 21335425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
    McKenna CE; Kashemirov BA; Błazewska KM; Mallard-Favier I; Stewart CA; Rojas J; Lundy MW; Ebetino FH; Baron RA; Dunford JE; Kirsten ML; Seabra MC; Bala JL; Marma MS; Rogers MJ; Coxon FP
    J Med Chem; 2010 May; 53(9):3454-64. PubMed ID: 20394422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
    Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
    Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
    Wiemer AJ; Tong H; Swanson KM; Hohl RJ
    Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.
    Haney SL; Wills VS; Wiemer DF; Holstein SA
    Molecules; 2017 May; 22(6):. PubMed ID: 28555000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
    Thompson K; Dunford JE; Ebetino FH; Rogers MJ
    Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patent review of bisphosphonates in treating bone disease.
    Holstein SA
    Expert Opin Ther Pat; 2019 May; 29(5):315-325. PubMed ID: 31023104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.
    Haney SL; Varney ML; Chhonker Y; Talmon G; Smith LM; Murry DJ; Holstein SA
    Pharmacol Res; 2021 May; 167():105528. PubMed ID: 33667685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors.
    Lacbay CM; Waller DD; Park J; Gómez Palou M; Vincent F; Huang XF; Ta V; Berghuis AM; Sebag M; Tsantrizos YS
    J Med Chem; 2018 Aug; 61(15):6904-6917. PubMed ID: 30016091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase.
    Holstein SA; Cermak DM; Wiemer DF; Lewis K; Hohl RJ
    Bioorg Med Chem; 1998 Jun; 6(6):687-94. PubMed ID: 9681134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new motif for inhibitors of geranylgeranyl diphosphate synthase.
    Foust BJ; Allen C; Holstein SA; Wiemer DF
    Bioorg Med Chem; 2016 Aug; 24(16):3734-41. PubMed ID: 27338660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.
    Wasko BM; Smits JP; Shull LW; Wiemer DF; Hohl RJ
    J Lipid Res; 2011 Nov; 52(11):1957-64. PubMed ID: 21903868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells.
    Hechinger AK; Maas K; Dürr C; Leonhardt F; Prinz G; Marks R; Gerlach U; Hofmann M; Fisch P; Finke J; Pircher H; Zeiser R
    Haematologica; 2013 Jan; 98(1):31-40. PubMed ID: 22801964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.